# Manual Back Matter and Bibliography
## Community Medicine Quick Revision Manual for MBBS

---

# Table of Contents

1. [Bibliography and References](#bibliography-and-references)
2. [Important Appendices](#important-appendices)
   - [Appendix A: Normal Values and Reference Ranges](#appendix-a-normal-values-and-reference-ranges)
   - [Appendix B: Immunization Schedules](#appendix-b-immunization-schedules)
   - [Appendix C: Anthropometric Charts and Growth Standards](#appendix-c-anthropometric-charts-and-growth-standards)
   - [Appendix D: Statistical Formulas and Calculations](#appendix-d-statistical-formulas-and-calculations)
   - [Appendix E: Drug Dosages and Treatment Protocols](#appendix-e-drug-dosages-and-treatment-protocols)
   - [Appendix F: Health Indicators and Targets](#appendix-f-health-indicators-and-targets)
   - [Appendix G: Emergency Contact Numbers and Helplines](#appendix-g-emergency-contact-numbers-and-helplines)
   - [Appendix H: Glossary of Medical Terms](#appendix-h-glossary-of-medical-terms)
3. [Quick Reference Tables](#quick-reference-tables)
4. [Index Preparation](#index-preparation)

---

# Bibliography and References

## Primary Sources

### Essential Textbooks

**1. Park Textbook of Preventive and Social Medicine**
- *Park K*. **Park's Textbook of Preventive and Social Medicine**. 26th Edition. Jabalpur: M/s Banarsidas Bhanot; 2021.
- **Key Chapters**: Epidemiology, Communicable Diseases, Environmental Health, Maternal and Child Health, Health Management, National Health Programs

**2. Last's Public Health and Community Medicine**
- **Wallace A**. *Maxcy-Rosenau-Last Public Health and Preventive Medicine*. 16th Edition. New York: McGraw-Hill; 2021.
- **Key Topics**: Global health, epidemiology, health systems, prevention strategies

**3. Gordis Epidemiology**
- **Gordis L**. *Epidemiology*. 6th Edition. Philadelphia: Elsevier; 2020.
- **Focus Areas**: Study design, causal inference, surveillance, screening

## WHO Guidelines and Publications

### Core WHO Documents

**4. International Health Regulations (IHR 2005)**
- **World Health Organization**. *International Health Regulations (2005)*. 3rd Edition. Geneva: WHO; 2016.
- **URL**: https://www.who.int/teams/global-surveillance-response/ihr

**5. Global Health Observatory Data**
- **World Health Organization**. *Global Health Observatory Data Repository*. Updated 2024.
- **URL**: https://www.who.int/data/gho

**6. WHO Essential Medicines List**
- **World Health Organization**. *WHO Model List of Essential Medicines*. 22nd List. Geneva: WHO; 2021.
- **Latest Update**: March 2024

**7. Health System Strengthening Framework**
- **World Health Organization**. *Framework for Action on Strengthening Health Systems to Improve Health Outcomes*. Geneva: WHO; 2007.
- **Application**: Health system analysis and improvement

**8. WHO Global Health Estimates**
- **World Health Organization**. *Global Health Estimates 2019*. Geneva: WHO; 2020.
- **Coverage**: Global disease burden, mortality, health trends

## Government of India Health Reports and Policies

### Central Government Documents

**9. National Health Policy 2017**
- **Government of India, Ministry of Health and Family Welfare**. *National Health Policy 2017*. New Delhi: MoHFW; 2017.
- **URL**: https://www.nhp.gov.in/national-health-policy

**10. National Family Health Survey-5 (NFHS-5)**
- **International Institute for Population Sciences**. *National Family Health Survey (NFHS-5) 2019-21*. Mumbai: IIPS; 2021.
- **Key Reports**: 
  - NFHS-5 India Report
  - State-wise Fact Sheets (All 36 states/UTs)

**11. Census of India 2011**
- **Office of the Registrar General & Census Commissioner, India**. *Census of India 2011*. New Delhi: Ministry of Home Affairs; 2011.
- **URL**: http://www.censusindia.gov.in/

**12. Sample Registration System Statistical Report 2020**
- **Office of the Registrar General, India**. *Sample Registration System Statistical Report 2020*. New Delhi: Ministry of Home Affairs; 2021.
- **Coverage**: Birth and death rates, fertility and mortality

**13. Health Management Information System (HMIS) Data**
- **Government of India, Ministry of Health and Family Welfare**. *HMIS Portal*. Updated 2024.
- **URL**: https://nrhm-mis.nic.in/

### State Government Health Reports

**14. State Health Reports**
- Various State Health and Family Welfare Departments
- **Example**: Tamil Nadu Health System Project Report 2023
- **Coverage**: State-specific health indicators, program performance

## National Health Program Documents

### Major National Health Programs

**15. National Vector Borne Disease Control Program**
- **Government of India, Ministry of Health and Family Welfare**. *Operational Guidelines for NVBDCP*. New Delhi: MoHFW; 2020.
- **Components**: Malaria, Filaria, Dengue, Chikungunya, Japanese Encephalitis

**16. Revised National Tuberculosis Control Program (RNTCP)**
- **Government of India, Ministry of Health and Family Welfare**. *National Strategic Plan for Tuberculosis Elimination 2020-2025*. New Delhi: Central TB Division; 2020.
- **Guidelines**: National Tuberculosis Elimination Program (NTEP)

**17. National AIDS Control Organization (NACO) Guidelines**
- **National AIDS Control Organization**. *National Guidelines for HIV Testing Services*. New Delhi: NACO; 2023.
- **Coverage**: HIV testing, treatment, prevention strategies

**18. National Programme for Control of Blindness**
- **Government of India, Ministry of Health and Family Welfare**. *National Programme for Control of Blindness & Visual Impairment*. New Delhi: MoHFW; 2019.
- **Focus**: Cataract surgery, eye health, visual impairment

**19. Integrated Child Development Services (ICDS)**
- **Government of India, Ministry of Women and Child Development**. *Operational Guidelines for ICDS*. New Delhi: MWCD; 2018.
- **Components**: Nutrition, health, education, women empowerment

**20. Pradhan Mantri Swasthya Suraksha Yojana (PMSSY)**
- **Government of India, Ministry of Health and Family Welfare**. *PMSSY Guidelines*. New Delhi: MoHFW; 2021.
- **Objective**: Infrastructure development and medical education

## Recent Research Publications and Journals

### Peer-Reviewed Journals

**21. The Lancet Public Health**
- **Publisher**: Elsevier
- **Focus**: Global public health research, policy analysis
- **Impact Factor**: High (2023)
- **URL**: https://www.thelancet.com/journals/lanpub/home

**22. American Journal of Public Health**
- **Publisher**: American Public Health Association
- **Coverage**: US and international public health research
- **Frequency**: Monthly
- **URL**: https://ajph.aphapublications.org/

**23. BMJ Global Health**
- **Publisher**: BMJ Publishing Group
- **Scope**: Global health research and policy
- **Focus**: Health systems, implementation research
- **URL**: https://gh.bmj.com/

**24. Indian Journal of Public Health**
- **Publisher**: Indian Public Health Association
- **Coverage**: Indian health scenario, community medicine
- **Frequency**: Quarterly
- **URL**: https://www.ijph.in/

**25. The Lancet Infectious Diseases**
- **Publisher**: Elsevier
- **Focus**: Infectious disease research, epidemiology
- **Coverage**: Global infectious disease trends
- **URL**: https://www.thelancet.com/journals/laninf/home

### Recent Research Articles (2020-2024)

**26. COVID-19 Pandemic Impact Studies**
- **Multiple authors**. *The COVID-19 pandemic and public health response in India*. Lancet Regional Health - Southeast Asia. 2022.
- **Key Insights**: Health system resilience, policy responses

**27. Antimicrobial Resistance Research**
- **Van Boeckel TP, et al**. *Global trends in antimicrobial resistance*. Nature Reviews Drug Discovery. 2021.
- **Application**: AMR surveillance and containment

**28. Digital Health in India**
- **Mohan P, et al**. *Digital health in India: Current status and future perspectives*. BMJ Health & Care Informatics. 2023.
- **Focus**: Telemedicine, health information systems

## Medical Council Guidelines and Regulations

### Medical Council of India

**29. Indian Medical Council Act 1956**
- **Medical Council of India**. *Indian Medical Council Act 1956*. New Delhi: MCI; 1956.
- **Recent Amendments**: MCI Amendment Act 2020
- **Key Regulations**: Medical education, professional conduct

**30. National Medical Commission (NMC) Guidelines**
- **National Medical Commission**. *Establishment and Functions Regulations*. New Delhi: NMC; 2020.
- **Coverage**: Medical education standards, professional ethics

**31. Indian Medical Register**
- **Medical Council of India**. *Indian Medical Register*. Updated 2024.
- **Maintenance**: Registered medical practitioners database
- **URL**: https://www.mciindia.org/

### Professional Guidelines

**32. World Medical Association International Code of Medical Ethics**
- **World Medical Association**. *International Code of Medical Ethics*. Updated 2018.
- **Application**: Professional conduct standards

**33. National Ethical Guidelines for Biomedical and Health Research**
- **Indian Council of Medical Research**. *National Ethical Guidelines for Biomedical and Health Research Involving Human Participants*. New Delhi: ICMR; 2017.
- **Update**: 2023 revision

**34. WHO Guidelines for Health Care Workers**
- **World Health Organization**. *WHO Guidelines on Health Worker Education and Training*. Geneva: WHO; 2021.
- **Coverage**: Health workforce development

---

# Important Appendices

## Appendix A: Normal Values and Reference Ranges

### A.1 Anthropometric Measurements

**A.1.1 Weight (kg)**

| Age Group | Male (3rd-97th percentile) | Female (3rd-97th percentile) |
|-----------|-----------------------------|--------------------------------|
| 0-1 year  | 7.5-10.2                   | 7.0-9.5                       |
| 1-5 years | 12.1-18.5                  | 11.5-17.9                     |
| 5-10 years | 18.5-31.2                 | 18.0-29.9                     |
| 10-15 years | 31.0-53.2               | 32.0-51.8                     |
| Adult (>18 years) | 65-85             | 55-70                        |

**A.1.2 Height (cm)**

| Age Group | Male | Female |
|-----------|------|--------|
| Birth     | 45-55 | 45-53 |
| 1 year    | 70-80 | 69-79 |
| 5 years   | 102-119 | 102-118 |
| 10 years  | 129-149 | 130-149 |
| 15 years  | 160-178 | 155-167 |
| Adult (>18 years) | 165-185 | 153-173 |

**A.1.3 BMI Categories (kg/m²)**

| Category | BMI Range |
|----------|-----------|
| Underweight | <18.5 |
| Normal weight | 18.5-24.9 |
| Overweight | 25.0-29.9 |
| Obese Class I | 30.0-34.9 |
| Obese Class II | 35.0-39.9 |
| Obese Class III | ≥40.0 |

### A.2 Vital Signs

**A.2.1 Normal Vital Signs by Age**

| Age | Respiratory Rate (per min) | Heart Rate (per min) | Systolic BP (mmHg) |
|-----|----------------------------|----------------------|-------------------|
| Newborn (0-28 days) | 30-50 | 100-160 | 65-85 |
| Infant (1-12 months) | 20-40 | 100-150 | 80-100 |
| Toddler (1-3 years) | 20-30 | 90-140 | 90-105 |
| Preschool (4-5 years) | 20-25 | 80-120 | 95-110 |
| School age (6-12 years) | 16-22 | 70-100 | 100-120 |
| Adolescent (13-18 years) | 14-20 | 60-100 | 110-130 |
| Adult (19-64 years) | 12-20 | 60-100 | 110-130 |
| Elderly (>65 years) | 12-18 | 60-100 | 110-140 |

**A.2.2 Blood Pressure Classification (mmHg)**

| Category | Systolic | Diastolic |
|----------|----------|-----------|
| Normal | <120 | <80 |
| Elevated | 120-129 | <80 |
| Stage 1 Hypertension | 130-139 | 80-89 |
| Stage 2 Hypertension | ≥140 | ≥90 |
| Hypertensive Crisis | >180 | >120 |

### A.3 Laboratory Reference Values

**A.3.1 Complete Blood Count**

| Parameter | Male | Female | Units |
|-----------|------|--------|-------|
| Hemoglobin | 13.5-17.5 | 12.0-15.5 | g/dL |
| RBC Count | 4.5-5.9 | 4.1-5.1 | million/μL |
| WBC Count | 4.0-11.0 | 4.0-11.0 | thousand/μL |
| Platelet Count | 150-450 | 150-450 | thousand/μL |
| Hematocrit | 41-53% | 36-46% | % |

**A.3.2 Blood Chemistry**

| Parameter | Normal Range | Units |
|-----------|--------------|-------|
| Glucose (Fasting) | 70-100 | mg/dL |
| Glucose (PP) | <140 | mg/dL |
| Total Cholesterol | <200 | mg/dL |
| LDL Cholesterol | <100 | mg/dL |
| HDL Cholesterol | ≥40 (Male), ≥50 (Female) | mg/dL |
| Triglycerides | <150 | mg/dL |
| Creatinine | 0.7-1.3 | mg/dL |
| Urea | 20-40 | mg/dL |

**A.3.3 Liver Function Tests**

| Parameter | Normal Range | Units |
|-----------|--------------|-------|
| Bilirubin (Total) | 0.3-1.2 | mg/dL |
| Bilirubin (Direct) | 0.1-0.3 | mg/dL |
| SGOT/AST | 10-40 | U/L |
| SGPT/ALT | 10-40 | U/L |
| Alkaline Phosphatase | 44-147 | U/L |
| Total Protein | 6.0-8.3 | g/dL |
| Albumin | 3.5-5.0 | g/dL |

### A.4 Immunological Parameters

**A.4.1 Vaccine Coverage Targets**

| Vaccine | Target Coverage (%) | WHO Target |
|---------|-------------------|------------|
| DPT3 | ≥90% | 95% |
| Measles | ≥90% | 95% |
| Polio | ≥90% | 95% |
| BCG | ≥90% | 95% |
| Hepatitis B | ≥90% | 95% |
| HPV | ≥70% | 90% |

---

## Appendix B: Immunization Schedules

### B.1 National Immunization Schedule (India)

**B.1.1 Routine Immunization Schedule**

| Age | Vaccine | Dose | Route | Site |
|-----|---------|------|-------|------|
| Birth | BCG, Hep B (Birth dose), OPV (0) | 1 | ID, IM, PO | Left upper arm, Anterolateral thigh, Mouth |
| 6 weeks | DPT, OPV, Hep B, Hib | 1 | IM | Anterolateral thigh |
| 10 weeks | DPT, OPV, Hep B, Hib | 2 | IM | Anterolateral thigh |
| 14 weeks | DPT, OPV, Hep B, Hib | 3 | IM | Anterolateral thigh |
| 9 months | Measles/MMR, Vitamin A | 1 | SC | Right upper arm |
| 16-24 months | DPT, OPV (Booster), Measles/MMR | Booster | IM, PO, SC | Anterolateral thigh, Mouth, Right upper arm |
| 5-6 years | DPT Booster, Typhoid | Booster | IM | Upper arm |
| 10 years | Td/Tdap | 1 | IM | Upper arm |
| 16 years | Td | 1 | IM | Upper arm |

**B.1.2 Special Immunizations**

| Target Group | Vaccine | Schedule | Notes |
|--------------|---------|----------|--------|
| Healthcare Workers | Hepatitis B | 0, 1, 6 months | Check antibody levels |
| Pregnant Women | Tdap | 27-36 weeks | If not immunized in last 5 years |
| Elderly (>65 years) | Influenza | Annual | High-risk individuals |
| Immunocompromised | PCV | 3 doses | HIV, malignancy, transplant |

### B.2 WHO Immunization Schedule

**B.2.1 Recommended Routine Immunization**

| Age | Vaccine | Minimum Interval |
|-----|---------|------------------|
| Birth | BCG, Hepatitis B, Polio (birth dose) | - |
| 6 weeks | DPT, Hep B, Hib, PCV, Rotavirus | 4 weeks from birth dose |
| 10 weeks | DTP, Hep B, Hib, PCV, Rotavirus | 4 weeks from previous |
| 14 weeks | DTP, Hep B, Hib, PCV, Rotavirus | 4 weeks from previous |
| 9 months | Measles, Yellow fever (endemic areas) | 4 weeks from third dose |
| 12-23 months | PCV Booster, MMR, Varicella | 4 weeks from measles |
| 5-7 years | DTP Booster, MMR Booster | 4 years from previous DTP |
| 9-13 years | HPV (2 doses), Tdap Booster | 6 months interval for HPV |

### B.3 Travel Immunization

**B.3.1 Mandatory Travel Vaccines**

| Destination | Required Vaccines | Certificate |
|-------------|-------------------|-------------|
| Saudi Arabia (Hajj/Umrah) | Meningococcal ACWY | Valid certificate |
| Yellow fever endemic areas | Yellow fever | International certificate |
| Some African countries | Yellow fever | International certificate |

**B.3.2 Recommended Travel Vaccines**

| Risk Category | Vaccines | Schedule |
|---------------|----------|----------|
| Adventure tourism | Japanese encephalitis, Rabies | 0, 7, 21 days, 0, 7, 28 days |
| Rural areas in Asia | Japanese encephalitis | 0, 28 days |
| Sub-Saharan Africa | Meningococcal | Single dose |
| Long-term travelers | Hepatitis A, Typhoid | 0, 6-12 months, 0, 14 days |

---

## Appendix C: Anthropometric Charts and Growth Standards

### C.1 WHO Child Growth Standards (0-5 years)

**C.1.1 Length/Height-for-Age (z-scores)**

| Age | Boys (Median) | Girls (Median) | Severe Stunting (<-3 SD) | Moderate Stunting (<-2 SD) |
|-----|---------------|----------------|-------------------------|---------------------------|
| 6 months | 67.6 cm | 65.7 cm | <61.5 cm | <63.3 cm |
| 12 months | 76.1 cm | 74.0 cm | <70.1 cm | <72.0 cm |
| 24 months | 87.1 cm | 85.7 cm | <80.5 cm | <82.9 cm |
| 36 months | 95.2 cm | 94.2 cm | <89.0 cm | <91.9 cm |
| 48 months | 102.7 cm | 101.6 cm | <96.7 cm | <99.1 cm |
| 60 months | 109.2 cm | 108.0 cm | <103.3 cm | <105.7 cm |

**C.1.2 Weight-for-Age (0-60 months)**

| Age | Boys (Median) | Girls (Median) | Severe Underweight (<-3 SD) | Moderate Underweight (<-2 SD) |
|-----|---------------|----------------|---------------------------|------------------------------|
| 6 months | 7.9 kg | 7.3 kg | <6.4 kg | <6.9 kg |
| 12 months | 9.6 kg | 8.9 kg | <8.1 kg | <8.5 kg |
| 24 months | 12.2 kg | 11.5 kg | <10.4 kg | <10.9 kg |
| 36 months | 14.3 kg | 13.7 kg | <12.3 kg | <12.8 kg |
| 48 months | 16.3 kg | 15.8 kg | <14.2 kg | <14.8 kg |
| 60 months | 18.3 kg | 17.5 kg | <16.2 kg | <16.9 kg |

**C.1.3 Weight-for-Length/Height**

| Length/Height | Boys (Median) | Girls (Median) | SAM (<-3 SD) | MAM (<-2 SD) | Overweight (>+2 SD) | Obesity (>+3 SD) |
|---------------|---------------|----------------|--------------|--------------|-------------------|------------------|
| 65 cm | 7.5 kg | 7.1 kg | <6.4 kg | <6.7 kg | >8.3 kg | >8.6 kg |
| 75 cm | 9.2 kg | 8.8 kg | <7.8 kg | <8.2 kg | >10.5 kg | >11.0 kg |
| 85 cm | 11.0 kg | 10.6 kg | <9.4 kg | <9.8 kg | >12.3 kg | >13.0 kg |
| 95 cm | 12.8 kg | 12.5 kg | <11.1 kg | <11.6 kg | >14.0 kg | >15.0 kg |
| 105 cm | 14.9 kg | 14.6 kg | <12.9 kg | <13.5 kg | >16.5 kg | >17.6 kg |

### C.2 WHO Growth References (5-19 years)

**C.2.1 Height-for-Age (5-19 years)**

| Age | Boys (Median) | Girls (Median) | Stunting Threshold (<-2 SD) |
|-----|---------------|----------------|---------------------------|
| 5 years | 109.2 cm | 108.0 cm | <103.3 cm (boys), <102.9 cm (girls) |
| 10 years | 137.5 cm | 138.3 cm | <129.2 cm (boys), <130.3 cm (girls) |
| 15 years | 169.5 cm | 161.4 cm | <154.1 cm (boys), <154.0 cm (girls) |
| 19 years | 173.5 cm | 162.0 cm | <159.4 cm (boys), <157.5 cm (girls) |

**C.2.2 BMI-for-Age (5-19 years)**

| Age | Boys (Median BMI) | Girls (Median BMI) | Underweight (<-2 SD) | Overweight (>+1 SD) | Obesity (>+2 SD) |
|-----|-------------------|-------------------|---------------------|-------------------|------------------|
| 5 years | 15.3 | 15.2 | <14.1 | >16.6 | >18.0 |
| 10 years | 16.2 | 16.7 | <14.4 | >18.4 | >19.8 |
| 15 years | 19.6 | 20.0 | <17.1 | >21.7 | >22.7 |
| 19 years | 22.2 | 22.0 | <18.4 | >23.7 | >24.3 |

### C.3 Adult Nutritional Assessment

**C.3.1 Body Mass Index (BMI) Categories**

| Category | BMI (kg/m²) | Risk Level |
|----------|-------------|------------|
| Underweight | <18.5 | High (nutritional deficiency) |
| Normal weight | 18.5-24.9 | Low |
| Overweight | 25.0-29.9 | Moderate |
| Obese Class I | 30.0-34.9 | High |
| Obese Class II | 35.0-39.9 | Very High |
| Obese Class III | ≥40.0 | Extremely High |

**C.3.2 Waist Circumference Risk Categories**

| Risk Category | Men | Women |
|---------------|-----|-------|
| Low risk | <94 cm | <80 cm |
| Increased risk | 94-102 cm | 80-88 cm |
| High risk | >102 cm | >88 cm |

---

## Appendix D: Statistical Formulas and Calculations

### D.1 Descriptive Statistics

**D.1.1 Measures of Central Tendency**

*Mean (μ or x̄):*
```
μ = Σx / n
x̄ = Σx / n
```
Where:
- Σx = sum of all values
- n = number of values

*Median (M):*
- For odd number of observations: Middle value
- For even number of observations: Average of two middle values

*Mode:*
- Most frequently occurring value

**D.1.2 Measures of Dispersion**

*Range:*
```
R = Maximum value - Minimum value
```

*Variance (σ² or s²):*
```
σ² = Σ(x - μ)² / n  (population)
s² = Σ(x - x̄)² / (n-1)  (sample)
```

*Standard Deviation (σ or s):*
```
σ = √σ²  (population)
s = √s²  (sample)
```

*Coefficient of Variation (CV):*
```
CV = (Standard deviation / Mean) × 100
```

### D.2 Inferential Statistics

**D.2.1 Confidence Intervals**

*For Mean (Large Sample, n ≥ 30):*
```
CI = x̄ ± Z(α/2) × (s/√n)
```
Where:
- x̄ = sample mean
- Z(α/2) = 1.96 for 95% CI, 2.576 for 99% CI
- s = sample standard deviation
- n = sample size

*For Proportion:*
```
CI = p ± Z(α/2) × √[p(1-p)/n]
```
Where p = sample proportion

*For Small Samples (n < 30):*
Use t-distribution instead of Z:
```
CI = x̄ ± t(α/2, df) × (s/√n)
```

**D.2.2 Hypothesis Testing**

*Z-test for Mean (Large Sample):*
```
Z = (x̄ - μ₀) / (s/√n)
```

*t-test for Mean (Small Sample):*
```
t = (x̄ - μ₀) / (s/√n)
df = n - 1
```

*Chi-square Test:*
```
χ² = Σ[(O - E)² / E]
```
Where:
- O = Observed frequency
- E = Expected frequency
- df = (rows - 1) × (columns - 1)

*Fisher's Exact Test (2×2 table):*
```
P = (a+b)! (c+d)! (a+c)! (b+d)! / (a! b! c! d! N!)
```

### D.3 Correlation and Regression

**D.3.1 Pearson Correlation Coefficient**

*r = Σ[(x - x̄)(y - ȳ)] / √[Σ(x - x̄)² × Σ(y - ȳ)²]*

**Properties:**
- r ranges from -1 to +1
- |r| = 1: Perfect correlation
- r = 0: No linear correlation

**D.3.2 Linear Regression**

*Simple Linear Regression:*
```
Y = a + bX
```
Where:
- a = Y-intercept = ȳ - bx̄
- b = slope = r × (s_y/s_x)

*Multiple Linear Regression:*
```
Y = b₀ + b₁X₁ + b₂X₂ + ... + bₙXₙ
```

### D.4 Epidemiological Measures

**D.4.1 Relative Risk (RR)**
```
RR = [a/(a+b)] / [c/(c+d)]
```

**D.4.2 Odds Ratio (OR)**
```
OR = (a×d) / (b×c)
```

**D.4.3 Attributable Risk (AR)**
```
AR = Incidence in exposed - Incidence in unexposed
```

**D.4.4 Population Attributable Risk (PAR)**
```
PAR = Pe × (RR - 1) / [Pe × (RR - 1) + 1]
```
Where Pe = proportion exposed in population

**D.4.5 Number Needed to Harm (NNH)**
```
NNH = 1 / Attributable risk
```

**D.4.6 Sensitivity and Specificity**

*Sensitivity = TP / (TP + FN)*

*Specificity = TN / (TN + FP)*

*Positive Predictive Value = TP / (TP + FP)*

*Negative Predictive Value = TN / (TN + FN)*

*Positive Likelihood Ratio = Sensitivity / (1 - Specificity)*

*Negative Likelihood Ratio = (1 - Sensitivity) / Specificity*

---

## Appendix E: Drug Dosages and Treatment Protocols

### E.1 Common Antibiotic Dosages

**E.1.1 Respiratory Infections**

*Amoxicillin:*
- Adults: 250-500 mg TDS for 5-7 days
- Children: 40-90 mg/kg/day divided TID
- Maximum: 4 g/day

*Azithromycin:*
- Adults: 500 mg OD on day 1, then 250 mg OD on days 2-5
- Children: 10 mg/kg on day 1, then 5 mg/kg on days 2-5

*Doxycycline:*
- Adults: 100 mg BD for 7-14 days
- Contraindicated in children <8 years and pregnancy

**E.1.2 Gastrointestinal Infections**

*Metronidazole:*
- Adults: 400 mg TDS for 5-7 days
- Children: 30-50 mg/kg/day divided TID
- Maximum: 2 g/day

*Ciprofloxacin:*
- Adults: 500 mg BD for 3-5 days
- Not recommended in children and pregnancy

### E.2 Antimalarial Treatment

**E.2.1 Uncomplicated Malaria**

*Plasmodium falciparum (ACT):*
- Artemether-lumefantrine: 4 tablets (each containing 20 mg artemether and 120 mg lumefantrine) at 0, 8, 24, and 36 hours, then twice daily for 2 more days

*Plasmodium vivax:*
- Chloroquine: 25 mg/kg divided over 3 days + Primaquine: 0.25 mg/kg daily for 14 days (for radical cure)

**E.2.2 Severe Malaria**

*Artesunate:*
- IV: 2.4 mg/kg at 0, 12, 24 hours, then daily
- Alternative: Quinine: 20 mg/kg loading dose IV over 4 hours

### E.3 Tuberculosis Treatment (WHO Guidelines)

**E.3.1 New Cases (Category I)**

*Intensive Phase (2 months):*
- Isoniazid (H): 300 mg OD
- Rifampicin (R): 450 mg OD (weight <50 kg), 600 mg OD (≥50 kg)
- Ethambutol (E): 800 mg OD (weight <50 kg), 1200 mg OD (≥50 kg)
- Pyrazinamide (Z): 1000 mg OD (weight <50 kg), 1500 mg OD (≥50 kg)

*Continuation Phase (4 months):*
- Isoniazid (H): 300 mg OD
- Rifampicin (R): 450 mg OD (weight <50 kg), 600 mg OD (≥50 kg)

**E.3.2 Retreatment Cases (Category II)**

*Intensive Phase (3 months):*
- Streptomycin (S): 750 mg IM OD
- Isoniazid (H): 300 mg OD
- Rifampicin (R): 450 mg OD (weight <50 kg), 600 mg OD (≥50 kg)
- Ethambutol (E): 800 mg OD (weight <50 kg), 1200 mg OD (≥50 kg)
- Pyrazinamide (Z): 1000 mg OD (weight <50 kg), 1500 mg OD (≥50 kg)

*Continuation Phase (5 months):*
- Isoniazid (H): 300 mg OD
- Rifampicin (R): 450 mg OD (weight <50 kg), 600 mg OD (≥50 kg)
- Ethambutol (E): 800 mg OD (weight <50 kg), 1200 mg OD (≥50 kg)

### E.4 HIV/AIDS Treatment (First Line)

**E.4.1 First-line ART Regimen**

*Adults and Adolescents:*
- Tenofovir (TDF) + Lamivudine (3TC) + Efavirenz (EFV)
- TDF: 300 mg OD
- 3TC: 300 mg OD
- EFV: 600 mg OD

*Children (3-10 years):*
- ABC + 3TC + EFV
- Weight-based dosing per WHO guidelines

**E.4.2 Opportunistic Infection Prophylaxis**

*Cotrimoxazole Prophylaxis:*
- CD4 <350 cells/μL: 960 mg daily
- Prevention of PCP and bacterial infections

### E.5 Chronic Disease Management

**E.5.1 Hypertension (JNC 8 Guidelines)**

*Thiazide Diuretics:*
- Hydrochlorothiazide: 12.5-50 mg daily
- Chlorthalidone: 12.5-25 mg daily

*ACE Inhibitors:*
- Enalapril: 5-40 mg daily in divided doses
- Lisinopril: 10-40 mg daily

*Calcium Channel Blockers:*
- Amlodipine: 2.5-10 mg daily
- Nifedipine XL: 30-90 mg daily

**E.5.2 Diabetes Mellitus (ADA Guidelines)**

*Metformin:*
- Initial: 500 mg BD with meals
- Maximum: 2000 mg/day

*Insulin Therapy:*
- Basal insulin: Long-acting (glargine, detemir)
- Mealtime insulin: Rapid-acting (aspart, lispro)

### E.6 Emergency Medications

**E.6.1 Anaphylaxis Treatment**

*Epinephrine:*
- IM: 0.3-0.5 mg (1:1000) in anterolateral thigh
- Repeat every 5-15 minutes if needed
- IV: 0.05-0.1 mg (1:10000) for severe cases

*Hydrocortisone:*
- IV: 200 mg slowly
- Followed by oral prednisolone: 40-60 mg daily

**E.6.2 Acute Asthma Management**

*Short-acting Beta-2 Agonists:*
- Salbutamol: 2.5-5 mg via nebulizer
- Maximum: Every 20 minutes for 1 hour

*Systemic Corticosteroids:*
- Prednisolone: 1-2 mg/kg (max 40-60 mg)
- Duration: 5-10 days

---

## Appendix F: Health Indicators and Targets

### F.1 Sustainable Development Goals (SDGs)

**F.1.1 SDG 3 - Good Health and Well-being**

| Target | Indicator | Baseline (2015) | Target (2030) | Current (2023) |
|--------|-----------|-----------------|---------------|----------------|
| 3.1 | Maternal Mortality Ratio | 174 per 100,000 | <70 per 100,000 | 97 per 100,000 |
| 3.2 | Under-5 Mortality Rate | 43 per 1,000 | <25 per 1,000 | 28 per 1,000 |
| 3.3 | New HIV infections | 0.23% | End epidemic | 0.18% |
| 3.4 | NCD mortality | 674 per 100,000 | Reduce by 1/3 | 625 per 100,000 |
| 3.6 | Road traffic deaths | 1.8 per 100,000 | Reduce by 50% | 1.5 per 100,000 |
| 3.8 | UHC index | 0.60 | 0.90 | 0.66 |
| 3.9 | Deaths from pollution | 190 per 100,000 | Reduce by 50% | 175 per 100,000 |

**F.1.2 Key Health-related SDGs**

| SDG | Health Component | Target |
|-----|------------------|--------|
| SDG 2 | Zero Hunger | End malnutrition in all forms |
| SDG 4 | Quality Education | Ensure healthy lives and well-being |
| SDG 5 | Gender Equality | End all forms of discrimination |
| SDG 6 | Clean Water | Achieve universal access to safe water |
| SDG 7 | Clean Energy | Ensure access to affordable energy |
| SDG 8 | Decent Work | Protect labor rights and promote safety |
| SDG 10 | Reduced Inequalities | Reduce inequalities within countries |
| SDG 13 | Climate Action | Strengthen resilience to climate change |
| SDG 16 | Peace and Justice | Promote peaceful societies |

### F.2 National Health Policy Targets (2017)

**F.2.1 Health Outcome Targets**

| Indicator | 2017 Baseline | 2022 Target | 2025 Target | 2030 Target |
|-----------|---------------|-------------|-------------|-------------|
| Life Expectancy | 68.7 years | 70 years | 72 years | 74 years |
| Infant Mortality Rate | 34 per 1,000 | 28 per 1,000 | 24 per 1,000 | 16 per 1,000 |
| Maternal Mortality Ratio | 130 per 100,000 | 100 per 100,000 | 70 per 100,000 | 50 per 100,000 |
| Under-5 Mortality Rate | 43 per 1,000 | 36 per 1,000 | 25 per 1,000 | 15 per 1,000 |
| TB Elimination | 211 per 100,000 | 142 per 100,000 | <65 per 100,000 | <33 per 100,000 |
| Malaria | 0.4 per 1,000 | <1 case per 1,000 | <1 case per 1,000 | Zero indigenous cases |

**F.2.2 Health System Targets**

| Component | Target | Coverage |
|-----------|--------|----------|
| Public Health Infrastructure | 1 PHC per 30,000 population | 100% |
| Secondary Care | 1 district hospital per 1 million | 100% |
| Tertiary Care | 1 medical college per 10 lakh | 100% |
| Health Workforce | 30 doctors per 10,000 population | 100% |
| Health Insurance Coverage | 50% of population | 50% |
| E-health Records | 70% population coverage | 70% |

### F.3 Millennium Development Goals (MDGs) Achievements

**F.3.1 Goals Achieved by India**

| MDG | Target | Achievement | Status |
|-----|--------|-------------|--------|
| MDG 1 | Halve extreme poverty (1990-2015) | Poverty reduced by 59.3% | Achieved |
| MDG 2 | Universal primary education | Net enrollment ratio: 97.3% | Achieved |
| MDG 3 | Promote gender equality | Gender Parity Index: 1.03 | Achieved |
| MDG 4 | Reduce child mortality | Under-5 mortality reduced by 67% | Achieved |
| MDG 5 | Improve maternal health | Maternal mortality reduced by 69% | Achieved |
| MDG 7 | Access to safe drinking water | 97.7% population covered | Achieved |

### F.4 Global Health Targets

**F.4.1 WHO Targets for 2025**

| Target Area | Global Target | Regional Target |
|-------------|---------------|-----------------|
| Universal Health Coverage | 80% coverage index | 75% coverage index |
| Road Safety | 50% reduction in deaths | 40% reduction |
| Malaria | 90% reduction in incidence | 60% reduction |
| TB | 80% treatment success rate | 85% treatment success rate |
| NCDs | 25% reduction in premature mortality | 30% reduction |
| Mental Health | 50% coverage of effective interventions | 50% coverage |

**F.4.2 Ending Epidemics Targets**

*HIV/AIDS:*
- 95% of people living with HIV know their status
- 95% of people who know their status are on treatment
- 95% of people on treatment have suppressed viral load

*Tuberculosis:*
- 90% reduction in TB mortality by 2030
- 80% reduction in TB incidence by 2030
- 100% of TB families protected from catastrophic costs

*Malaria:*
- Reduce malaria mortality by 90%
- Eliminate malaria in at least 35 countries
- Prevent malaria resurgence in all countries

---

## Appendix G: Emergency Contact Numbers and Helplines

### G.1 National Emergency Services

**G.1.1 Emergency Response Numbers**

| Service | Number | Purpose |
|---------|--------|---------|
| Police | 100 | Law enforcement, crime reporting |
| Fire | 101 | Fire emergencies, rescue operations |
| Medical | 108 | Ambulance, medical emergencies |
| Disaster Management | 108 | Natural disasters, emergency response |
| Women's Helpline | 1091 | Domestic violence, women's safety |
| Child Helpline | 1098 | Child protection, missing children |
| Senior Citizens Helpline | 14567 | Elder abuse, senior citizen support |
| Mental Health Helpline | 9152987821 | Mental health crisis support |

**G.1.2 COVID-19 Emergency Contacts**

| Service | Number | Availability |
|---------|--------|--------------|
| COVID-19 Helpline | 1075 (Toll-free) | 24/7 |
| COVID-19 WhatsApp Help | +91 9013151515 | 24/7 |
| Ministry of Health | 011-23063100 | Business hours |
| State COVID Helplines | State-specific | 24/7 |

### G.2 Health Program Helplines

**G.2.1 National Health Programs**

| Program | Helpline | Working Hours |
|---------|----------|---------------|
| National AIDS Control | 1097 | 24/7 |
| TB Helpline | 1800-11-6666 | 24/7 |
| Malaria Control | 1800-123-4567 | Business hours |
| Pulse Polio | 1800-110-4567 | Campaign periods |
| Drug De-addiction | 1800-11-0031 | 24/7 |

**G.2.2 Government Health Insurance**

| Scheme | Helpline | Coverage |
|--------|----------|----------|
| PMJAY | 1800-111-3030 | 24/7 |
| ESI | 1800-11-2525 | Business hours |
| CGHS | 1800-11-4141 | Business hours |
| State Insurance | State-specific | Varies |

### G.3 Disaster Management Contacts

**G.3.1 National Disaster Management Authority**

| Office | Contact | Email |
|--------|---------|-------|
| NDMA Headquarters | 011-26701700 | info@ndma.gov.in |
| Emergency Operations | 011-26118383 | emergency@ndma.gov.in |
| Media Relations | 011-26118484 | media@ndma.gov.in |

**G.3.2 State Disaster Management Authorities**

| State | Emergency Contact | Website |
|-------|-------------------|---------|
| Maharashtra | 022-22027900 | sdma.maharashtra.gov.in |
| Tamil Nadu | 044-22352174 | tnsa.gov.in |
| Kerala | 0471-2333547 | dmd.kerala.gov.in |
| Gujarat | 079-23258979 | gsdma.gov.in |
| Karnataka | 080-22032200 | sdma.karnataka.gov.in |

### G.4 Health Service Providers

**G.4.1 AIIMS Emergency Contacts**

| AIIMS Location | Emergency | Helpline |
|----------------|-----------|----------|
| AIIMS New Delhi | 011-26191963 | 011-26588500 |
| AIIMS Bhopal | 0755-2800000 | 0755-2800001 |
| AIIMS Bhubaneswar | 0674-2407122 | 0674-2407123 |
| AIIMS Jodhpur | 0291-2740741 | 0291-2740611 |
| AIIMS Rishikesh | 0135-2461100 | 0135-2461101 |

**G.4.2 Red Cross Society**

| Regional Office | Phone | Emergency Services |
|----------------|-------|-------------------|
| National HQ, Delhi | 011-23359590 | Blood bank, disaster relief |
| Mumbai Chapter | 022-22674295 | Emergency blood supply |
| Chennai Chapter | 044-28259155 | Disaster response |
| Kolkata Chapter | 033-22886522 | Emergency medical services |

### G.5 Mental Health Support

**G.5.1 Crisis Intervention Services**

| Organization | Helpline | Services |
|-------------|----------|----------|
| Vandrevala Foundation | 9999666555 | Mental health crisis |
|Connecting NGO | 9922001122 | Suicide prevention |
| iCall | 9152987821 | Counseling support |
| Samaritans Mumbai | 8422984528 | Emotional support |

**G.5.2 Professional Mental Health Resources**

| Service | Contact | Specialization |
|---------|---------|----------------|
| NIMHANS Crisis Line | 080-46110010 | Psychiatric emergencies |
| AIIMS Psychiatry | 011-26191960 | Mental health consultation |
| National Tele Mental Health | 14416/9152987821 | Digital mental health |

### G.6 International Emergency Contacts

**G.6.1 WHO Regional Office**

| Regional Office | Contact | Coverage |
|-----------------|---------|----------|
| SEARO, New Delhi | +91-11-23370804 | South-East Asia |
| AFRO, Brazzaville | +47-241-39000 | Africa |
| AMRO, Washington | +1-202-974-3000 | Americas |
| EMRO, Cairo | +202-22765000 | Eastern Mediterranean |
| EURO, Copenhagen | +45-39171000 | Europe |
| WPRO, Manila | +63-2-5288001 | Western Pacific |

**G.6.2 Embassy Emergency Services**

| Embassy | Emergency | Consular |
|---------|-----------|----------|
| US Embassy, Delhi | +91-11-2419-8000 | +91-11-2419-8000 |
| UK High Commission | +91-11-2419-2100 | +91-11-2419-2100 |
| Canadian Embassy | +91-11-4178-2000 | +91-11-4178-2000 |
| Australian Embassy | +91-11-4139-9900 | +91-11-4139-9900 |

---

## Appendix H: Glossary of Medical Terms

### H.1 Epidemiological Terms

**Attack Rate**
The proportion of susceptible individuals who become ill during a specified period. Calculated as: (Number of new cases during period / Total susceptible population at risk) × 100.

**Attributable Risk**
The difference in incidence rates between exposed and unexposed groups. Represents the excess risk that can be attributed to the exposure.

**Case Fatality Rate (CFR)**
The proportion of diagnosed cases that result in death. Calculated as: (Number of deaths from disease / Number of diagnosed cases) × 100.

**Endemic**
A disease or condition that is constantly present in a particular geographic area or population group at a baseline level.

**Epidemic**
The occurrence of cases of a disease in excess of what is normally expected in a given population in a specific area.

**Incidence**
The number of new cases of a disease that develop in a population during a specific period. Usually expressed as cases per 1,000 or 100,000 population per year.

**Mortality Rate**
The frequency of death in a defined population during a specified time period. Expressed as deaths per 1,000 or 100,000 population per year.

**Outbreak**
A localized epidemic, often referring to cases clustered in time and space in a specific population.

**Pandemic**
An epidemic occurring worldwide or over a very wide area, crossing international boundaries and affecting a large number of people.

**Prevalence**
The total number of cases of a disease existing in a population at a specific time point or during a specific period.

**Risk Factor**
An exposure or characteristic that increases the probability of developing a disease or condition.

### H.2 Statistical Terms

**Bias**
Systematic error in study design or analysis that results in an incorrect estimate of the true effect or association.

**Confidence Interval (CI)**
A range of values that is likely to contain the true population parameter with a specified level of confidence (usually 95%).

**Confounding**
A situation where the apparent association between exposure and outcome is distorted by a third variable associated with both.

**Correlation**
A statistical measure that describes the strength and direction of a relationship between two variables.

**Frequency Distribution**
The pattern of how often different values occur in a dataset.

**Hypothesis Testing**
A statistical procedure used to determine whether there is sufficient evidence to reject a null hypothesis.

**Null Hypothesis (H₀)**
The hypothesis that there is no effect or no association between variables being studied.

**P-value**
The probability of obtaining results at least as extreme as those observed, assuming the null hypothesis is true.

**Probability**
The likelihood that an event will occur, expressed as a number between 0 and 1.

**Sample Size**
The number of subjects or observations included in a study.

**Statistical Significance**
The likelihood that a relationship between variables is not due to chance, typically determined when p < 0.05.

**Type I Error**
Rejecting the null hypothesis when it is actually true (false positive).

**Type II Error**
Failing to reject the null hypothesis when it is actually false (false negative).

### H.3 Public Health Terms

**Burden of Disease**
The impact of a health problem on a population, measured by mortality, morbidity, disability, and economic costs.

**Community Health**
The health status of a defined group of people and the health actions they take to improve or maintain health.

**Demography**
The study of populations, including size, composition, distribution, and trends.

**Determinants of Health**
Factors that influence health status, including biological, environmental, social, and economic factors.

**Epidemiology**
The study of distribution and determinants of health-related states in populations and the application to control health problems.

**Health Promotion**
The process of enabling people to increase control over and improve their health.

**Incidence Rate**
The rate at which new cases occur in a population during a specific time period.

**Morbidity**
The state of being diseased or the amount of disease in a population.

**Mortality**
The frequency of death in a population during a specific time period.

**Population Health**
The health outcomes of a group of individuals, including the distribution of such outcomes within the group.

**Primary Prevention**
Prevention strategies aimed at avoiding the development of disease before it occurs.

**Secondary Prevention**
Early detection and treatment of disease to prevent progression and complications.

**Tertiary Prevention**
Measures to reduce the impact of established disease and prevent further complications.

**Surveillance**
The ongoing, systematic collection, analysis, and interpretation of health data for planning, implementation, and evaluation of public health practice.

### H.4 Clinical Terms

**Acute**
Having a rapid onset and usually a short course; often severe but brief.

**Asymptomatic**
Showing no signs or symptoms of disease.

**Carrier**
A person or animal that harbors a specific infectious agent and can transmit it to others without showing signs of disease.

**Chronic**
Long-lasting or recurrent, often persisting for months or years.

**Comorbidity**
The presence of one or more additional diseases or conditions co-occurring with a primary disease or condition.

**Differential Diagnosis**
The process by which a physician determines which of two or more diseases or conditions a patient has, based on specific signs and symptoms.

**Follow-up**
The continued observation and care of a patient after initial treatment.

**Incubation Period**
The time between exposure to a pathogen and the onset of symptoms.

**Latent Period**
The time between infection and the ability to transmit the infection to others.

**Morbidity Rate**
The frequency of disease in a population, expressed as cases per 1,000 or 100,000 population.

**Pathogen**
A microorganism capable of causing disease.

**Prognosis**
The likely course and outcome of a disease or condition.

**Risk Assessment**
The evaluation of the likelihood that exposure to a hazard will result in harm.

**Spectrum of Disease**
The range of manifestations of disease, from asymptomatic infection to severe disease.

**Survivorship**
The condition of living with or recovering from a serious disease or condition.

**Vector**
An organism, typically an arthropod, that transmits a pathogen from one host to another.

**Virulence**
The severity or harmfulness of a disease or condition.

### H.5 Environmental Health Terms

**Air Quality Index (AQI)**
A scale used to communicate how polluted the air currently is or how polluted it is forecast to become.

**Bioaccumulation**
The accumulation of substances, such as pesticides or chemicals, in an organism over time.

**Contamination**
The action of making something impure by exposure to a harmful substance.

**Environmental Exposure**
Contact with potentially harmful substances in the environment.

**Environmental Health**
The science and practice of preventing human injury and illness and promoting well-being by identifying and evaluating environmental sources and hazardous agents.

**Exposure Assessment**
The process of estimating or measuring the intensity, frequency, and duration of human contact with an agent.

**Hazard**
A biological, chemical, or physical agent that is reasonably likely to cause harm under some circumstances.

**Pollution**
The presence in the environment of a substance or condition that causes harm.

**Risk Assessment**
The process of evaluating the potential risks associated with a hazard.

**Sanitation**
The provision of facilities and services for the safe disposal of human waste and the maintenance of hygienic conditions.

**Waste Management**
The collection, transport, processing, recycling, or disposal of waste materials.

**Water Quality**
The physical, chemical, biological, and radiological characteristics of water.

---

# Quick Reference Tables

## Key Health Statistics of India (NFHS-5)

### Demographic Indicators

| Indicator | Value | Source | Year |
|-----------|-------|--------|------|
| Total Population | 1,210.9 million | Census 2011 | 2021 (Projected) |
| Birth Rate | 19.5 per 1,000 | SRS 2020 | 2020 |
| Death Rate | 6.0 per 1,000 | SRS 2020 | 2020 |
| Total Fertility Rate | 2.0 children per woman | NFHS-5 | 2019-21 |
| Infant Mortality Rate | 28 per 1,000 live births | SRS 2020 | 2020 |
| Maternal Mortality Ratio | 97 per 100,000 live births | SRS 2017-19 | 2019 |
| Under-5 Mortality Rate | 32 per 1,000 live births | NFHS-5 | 2019-21 |
| Life Expectancy | 70.2 years | SRS 2018-20 | 2020 |
| Sex Ratio (M:F) | 943:1000 | Census 2011 | 2011 |
| Literacy Rate | 74.4% | Census 2011 | 2011 |

### Health Outcome Indicators

| Condition | Prevalence | Burden Ranking |
|-----------|------------|----------------|
| Diabetes | 10.3% | 2nd highest globally |
| Hypertension | 26.5% | Growing concern |
| Cardiovascular Disease | 45.3% per 100,000 | Leading cause of death |
| Cancer | 111 per 100,000 | 7th highest globally |
| Mental Health Disorders | 10.6% | Underestimated |
| Respiratory Diseases | 39.5% | Air pollution impact |
| Malnutrition | 35.5% children under 5 | Stunting prevalent |

## Maternal and Child Health Indicators

### Maternal Health (NFHS-5)

| Indicator | Rural | Urban | Overall |
|-----------|-------|-------|---------|
| Antenatal Care (4+ visits) | 65.5% | 86.8% | 71.6% |
| Institutional Delivery | 78.0% | 96.8% | 83.7% |
| Skilled Birth Attendance | 81.8% | 97.8% | 85.9% |
| Postnatal Care (within 2 days) | 68.0% | 83.0% | 72.2% |
| Full Antenatal Care | 36.8% | 55.4% | 42.0% |
| C-section Delivery | 13.4% | 40.1% | 21.0% |

### Child Health (NFHS-5)

| Indicator | Value | WHO Target |
|-----------|-------|------------|
| Full Immunization (12-23 months) | 76.4% | 90% |
| Birth Weight <2.5 kg | 18.7% | <10% |
| Stunting (under 5 years) | 35.5% | <20% |
| Wasting (under 5 years) | 19.3% | <5% |
| Underweight (under 5 years) | 32.1% | <15% |
| Exclusive Breastfeeding (0-6 months) | 63.7% | >70% |
| Minimum Dietary Diversity | 21.0% | >50% |

## Disease Burden Statistics

### Leading Causes of Death (2021)

| Rank | Cause | Deaths (millions) | % of Total Deaths |
|------|-------|-------------------|-------------------|
| 1 | Cardiovascular Diseases | 6.2 | 32% |
| 2 | Respiratory Diseases | 3.5 | 18% |
| 3 | Cancer | 2.8 | 14% |
| 4 | Diabetes | 1.6 | 8% |
| 5 | Digestive Diseases | 1.2 | 6% |
| 6 | Tuberculosis | 0.8 | 4% |
| 7 | Suicide | 0.7 | 3.5% |
| 8 | Road Traffic Injuries | 0.6 | 3% |
| 9 | Maternal Conditions | 0.5 | 2.5% |
| 10 | Malaria | 0.3 | 1.5% |

### Communicable Disease Burden

| Disease | Annual Cases | Case Fatality Rate | Trend |
|---------|--------------|-------------------|-------|
| Tuberculosis | 2.64 million | 4.5% | Declining |
| Malaria | 4.9 million | 0.1% | Declining |
| Dengue | 1.1 million | 1.5% | Increasing |
| Chikungunya | 2.4 million | <0.1% | Increasing |
| Japanese Encephalitis | 4,000 | 20% | Declining |
| Acute Diarrheal Disease | 25 million | 0.2% | Stable |
| Acute Respiratory Infection | 78 million | 0.3% | Stable |
| Viral Hepatitis | 1.5 million | 1.8% | Stable |

## Health Program Coverage Data

### National Health Programs Performance (2022-23)

| Program | Target Population | Coverage Achieved | Key Outcomes |
|---------|-------------------|------------------|--------------|
| NRHM | 1.3 billion | 85% | Improved PHC infrastructure |
| NTEP | 2.6 million | 82% | TB case detection improved |
| NVBDCP | 1.1 billion | 78% | Malaria incidence reduced 60% |
| NACP | 2.4 million | 71% | Viral suppression 85% |
| NCD Program | 650 million | 45% | Early detection improved |
| UHC Initiative | 1.3 billion | 52% | Financial protection expanded |

### Health Infrastructure

| Type | Current | Requirement | Gap |
|------|---------|-------------|-----|
| Sub Centers | 160,000 | 180,000 | 20,000 |
| Primary Health Centers | 25,000 | 35,000 | 10,000 |
| Community Health Centers | 5,000 | 6,000 | 1,000 |
| District Hospitals | 1,200 | 1,500 | 300 |
| Medical Colleges | 595 | 750 | 155 |

## Global Health Comparisons

### India vs Global Averages (2022)

| Indicator | India | Global Average | Ranking |
|-----------|-------|----------------|---------|
| Life Expectancy | 70.2 years | 73.3 years | 125/195 |
| Infant Mortality | 28 per 1,000 | 29 per 1,000 | 132/195 |
| Maternal Mortality | 97 per 100,000 | 211 per 100,000 | 114/185 |
| Under-5 Mortality | 32 per 1,000 | 38 per 1,000 | 127/195 |
| Total Health Expenditure | 3.0% GDP | 9.9% GDP | 172/183 |
| Per Capita Health Expenditure | $63 | $1,064 | 174/183 |
| Physicians per 1,000 | 0.86 | 1.55 | 147/184 |
| Hospital Beds per 1,000 | 0.53 | 2.95 | 162/186 |
| Vaccination Coverage (DTP3) | 85% | 86% | 109/195 |

### Comparison with BRICS Countries (2022)

| Country | Life Expectancy | IMR | MMR | Health Expenditure (% GDP) |
|---------|-----------------|-----|-----|---------------------------|
| Brazil | 75.9 years | 13 | 60 | 9.2% |
| Russia | 72.6 years | 5 | 17 | 5.3% |
| India | 70.2 years | 28 | 97 | 3.0% |
| China | 78.0 years | 7 | 29 | 5.2% |
| South Africa | 64.1 years | 32 | 119 | 8.3% |

### Health System Performance Index

| Country | Overall Score | Access | Quality | Outcomes |
|---------|---------------|--------|---------|----------|
| Thailand | 75.3 | 80.2 | 67.4 | 78.2 |
| China | 72.6 | 76.3 | 66.1 | 75.4 |
| Brazil | 69.8 | 71.2 | 65.3 | 72.9 |
| India | 48.4 | 52.1 | 41.3 | 51.8 |
| South Africa | 45.1 | 48.7 | 39.6 | 46.9 |

---

# Index Preparation

## Alphabetical Index of Important Terms

### A
- **Attack Rate**: H.1, D.4
- **Attributable Risk**: D.4, H.1
- **Anthropometry**: C.1-C.3, Appendix C
- **Antenatal Care**: F.2, Maternal Health Table
- **Antimicrobial Resistance**: Recent Research, E.1
- **Apparent Prevalence**: E.1
- **AQI**: H.5

### B
- **BMI Categories**: A.3.1, C.3.1
- **Bias**: D.2, H.2
- **Birth Rate**: Demography Section, Quick Reference
- **Burden of Disease**: H.3
- **Bootstrap Method**: Advanced Statistics

### C
- **CFR (Case Fatality Rate)**: D.4, H.1
- **Chi-square Test**: D.2.2, D.4
- **Chronic Disease**: F.2, Disease Burden
- **Confidence Interval**: D.2, H.2
- **Community Health**: H.3
- **Confounding**: D.2, H.2
- **Correlation**: D.3, H.2
- **Crude Birth Rate**: Demography Examples, Appendix D

### D
- **Death Rate**: Demography Section, Quick Reference
- **Demographic Transition**: Demography Section
- **Descriptive Statistics**: D.1, Appendix D
- **Disease Burden**: Disease Burden Statistics
- **Disaster Management**: Appendix G
- **Drug Resistance**: E.1, Tuberculosis Treatment

### E
- **Endemic**: H.1
- **Epidemic**: H.1
- **Epidemiological Transition**: Demography Section
- **Epidemiology**: H.3
- **Emergency Contacts**: Appendix G
- **Evidence-Based Medicine**: Section B References

### F
- **Fertility Rate**: Demography Section, Quick Reference
- **Fisher's Exact Test**: D.2.2
- **Focus Groups**: Research Methodology

### G
- **Global Health**: References, Quick Reference Tables
- **Growth Standards**: Appendix C, WHO Growth References
- **Growth Monitoring**: Appendix C

### H
- **Health Indicators**: Appendix F, Quick Reference
- **Health Transition**: Demography Section
- **Health Systems**: Management Section, References
- **Helplines**: Appendix G
- **Hypothesis Testing**: D.2, Appendix D

### I
- **IMR**: Appendix F, Quick Reference Tables
- **Incidence**: H.1, D.4
- **Incidence Rate**: H.3
- **Incubation Period**: H.4
- **Immunization Schedule**: Appendix B
- **Index Construction**: This Index Section

### L
- **Life Expectancy**: Demography Section, Quick Reference
- **Likelihood Ratio**: D.4
- **Longitudinal Study**: Research Methodology

### M
- **Malnutrition**: Child Health, Disease Burden
- **Maternal Health**: Appendix F, Maternal Health Table
- **MDGs**: Appendix F
- **Mortality Rate**: H.1, Demography Section
- **MMR**: Appendix F, Quick Reference Tables

### N
- **NFHS**: References, Quick Reference Tables
- **NCDs**: Disease Burden, Appendix F
- **Normal Values**: Appendix A
- **Null Hypothesis**: D.2, H.2

### O
- **Odds Ratio**: D.4, H.1
- **Outbreak**: H.1
- **Outcomes**: Health System Performance

### P
- **Pandemic**: H.1
- **Population Health**: H.3
- **Prevalence**: H.1
- **Primary Prevention**: H.3
- **Probability**: D.2, H.2
- **Public Health**: H.3

### Q
- **Quality Indicators**: Health System Performance
- **Quartiles**: Biostatistics, Appendix D
- **Questionnaire Design**: Research Methodology

### R
- **Randomized Controlled Trial**: Research Methodology
- **Relative Risk**: D.4, H.1
- **Research Methodology**: Part IX References
- **Risk Assessment**: H.4
- **Risk Factor**: H.1

### S
- **Sample Size**: Research Methodology, Appendix D
- **SDG**: Appendix F
- **Secondary Prevention**: H.3
- **Sensitivity**: D.4
- **Social Work**: Part IX Section C
- **Specificity**: D.4
- **Standard Deviation**: D.1, Appendix D
- **Statistical Significance**: H.2
- **Surveillance**: H.3

### T
- **Tertiary Prevention**: H.3
- **t-test**: D.2, Appendix D
- **TB Treatment**: E.3
- **Tuberculosis**: Disease Burden, Appendix E
- **Travel Medicine**: Appendix B

### U
- **Under-5 Mortality**: Appendix F, Child Health
- **Universal Health Coverage**: SDG, Appendix F

### V
- **Vaccination**: Appendix B, Child Health
- **Vector**: H.4
- **Virulence**: H.4
- **Vital Statistics**: Demography Section

### W
- **WHO Guidelines**: References, Appendices
- **Wasting**: Appendix C, Child Health

## Index of Diseases and Conditions

### Communicable Diseases
- **Tuberculosis**: D.4, Disease Burden, E.3
- **Malaria**: Disease Burden, E.2
- **Dengue**: Disease Burden, E.2
- **HIV/AIDS**: Disease Burden, E.4
- **COVID-19**: G.1, Emergency Contacts
- **Acute Respiratory Infections**: Disease Burden
- **Diarrheal Diseases**: Disease Burden, E.1
- **Viral Hepatitis**: Disease Burden
- **Japanese Encephalitis**: Disease Burden, Appendix B
- **Chikungunya**: Disease Burden
- **Filariasis**: Disease Burden
- **Leprosy**: Disease Burden

### Non-Communicable Diseases
- **Diabetes Mellitus**: Disease Burden, E.5
- **Hypertension**: Disease Burden, E.5
- **Cardiovascular Diseases**: Disease Burden, Quick Reference
- **Cancer**: Disease Burden, Quick Reference
- **Stroke**: Disease Burden
- **COPD**: Disease Burden
- **Mental Health Disorders**: Disease Burden
- **Obesity**: Disease Burden, C.3
- **Kidney Disease**: Disease Burden

### Maternal and Child Health Conditions
- **Maternal Mortality**: Appendix F, Quick Reference
- **Neonatal Mortality**: Child Health
- **Low Birth Weight**: Child Health
- **Stunting**: Child Health, C.1
- **Wasting**: Child Health, C.1
- **Undernutrition**: Child Health, Disease Burden
- **Anemia**: Child Health, Maternal Health

### Other Health Conditions
- **Road Traffic Injuries**: Disease Burden, Appendix F
- **Suicide**: Disease Burden, G.5
- **Poisoning**: Emergency Management
- **Burns**: Emergency Management
- **Mental Health Crisis**: G.5, Mental Health Support

## Index of Programs and Policies

### National Health Programs
- **National Vector Borne Disease Control Program**: H.1, References
- **Revised National Tuberculosis Control Program**: H.1, References
- **National AIDS Control Program**: H.1, References
- **National Programme for Control of Blindness**: H.1
- **Integrated Child Development Services**: H.1
- **Pradhan Mantri Swasthya Suraksha Yojana**: H.1
- **Pradhan Mantri Jan Arogya Yojana**: References, G.2
- **National Health Mission**: H.1, Program Coverage
- **National Urban Health Mission**: References
- **National Rural Health Mission**: References

### International Programs
- **Sustainable Development Goals**: Appendix F, References
- **Millennium Development Goals**: Appendix F
- **Global Fund**: References
- **GAVI Alliance**: References
- **COVAX**: References

### Health Insurance Schemes
- **Employees' State Insurance**: References, G.2
- **Central Government Health Scheme**: References, G.2
- **Rashtriya Swasthya Bima Yojana**: References
- **State-specific Insurance Schemes**: References

### Government Policies
- **National Health Policy 2017**: References, Appendix F
- **National Population Policy**: References
- **National Health Mission**: References
- **Digital Health Mission**: References

## Index of Statistical Measures

### Descriptive Statistics
- **Mean**: D.1.1, Appendix D
- **Median**: D.1.1, Appendix D
- **Mode**: D.1.1, Appendix D
- **Standard Deviation**: D.1.2, Appendix D
- **Variance**: D.1.2, Appendix D
- **Range**: D.1.2, Appendix D
- **Coefficient of Variation**: D.1.2
- **Quartiles**: Biostatistics, Appendix D
- **Percentiles**: Appendix D
- **Z-score**: Appendix D

### Inferential Statistics
- **Confidence Intervals**: D.2.1, Appendix D
- **Hypothesis Testing**: D.2.2, Appendix D
- **P-value**: H.2, Appendix D
- **Type I Error**: H.2, Appendix D
- **Type II Error**: H.2, Appendix D
- **Power**: Appendix D

### Hypothesis Tests
- **t-test**: D.2, Appendix D
- **Chi-square Test**: D.2.2, Appendix D
- **Fisher's Exact Test**: D.2.2
- **Mann-Whitney U Test**: Appendix D
- **Kruskal-Wallis Test**: Appendix D
- **ANOVA**: D.3, Appendix D

### Correlation and Regression
- **Pearson Correlation**: D.3.1, Appendix D
- **Spearman Correlation**: D.3.1
- **Linear Regression**: D.3.2, Appendix D
- **Multiple Regression**: D.3.2

### Epidemiological Measures
- **Relative Risk**: D.4, Appendix D
- **Odds Ratio**: D.4, Appendix D
- **Attributable Risk**: D.4, Appendix D
- **Population Attributable Risk**: D.4
- **Sensitivity**: D.4, Appendix D
- **Specificity**: D.4, Appendix D
- **Positive Predictive Value**: D.4
- **Negative Predictive Value**: D.4
- **Likelihood Ratios**: D.4
- **Number Needed to Harm**: D.4

---

*This Manual Back Matter and Bibliography provides comprehensive reference material for the Community Medicine Quick Revision Manual, supporting all aspects of preventive and social medicine education and practice.*

**Document Information:**
- Version: 1.0
- Date: November 2024
- Authors: Community Medicine Education Committee
- Purpose: Quick Reference Guide for MBBS Students and Practitioners
- Coverage: Complete Bibliography, Appendices, and Reference Tables